The Global Antibiotic Research & Development Partnership (GARDP)

Editors in Conversation

Lack of access to antibiotics including those with enhanced activity against multidrug-resistant organisms is a major barrier to combat antimicrobial resistance, particularly in the developing world. Furthermore, discovering and making available new antimicrobial agents against the most pressing antibiotic-resitant organisms is a challenge due to multiple barriers. The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come. We discuss the important role that GARDP is playing in the worldwide fight against antimicrobial resistance.

Topics discussed:

• GARDP function and role in the AMR field
• The strategies that GARDP is implementing to make new antibiotics available to all
• The future of antimicrobial research and development and the role of GARDP in this process.

Guests:

• Jennifer Cohn MD MPH, Director, Global Access Global Antibiotic R&D Partnership (GARDP)
• Susana Ribeiro, MPH, Regional Head Latin America Global Antibiotic R&D Partnership (GARDP)

This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal.

Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.